Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.45 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8748156 | 0.84 | ALDH1A1 (0.52) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL966453 | 0.83 | CES2 (0.49) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL29993198 | 0.81 | MEN1 (0.49) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL8149039 | 0.81 | L3MBTL1 (0.50) | TSHRMAPK1IDO1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL12818175 | 0.77 | CES2 (0.46) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL27553074 | 0.76 | ALDH1A1 (0.51) | TSHRMAPK1IDO1MEN1KMT2A | |
| SCHEMBL11254225 | 0.76 | TP53 (0.50) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL19639789 | 0.74 | HDAC1 (0.47) | TSHRMEN1KMT2AALDH1A1CES2 | |
| SCHEMBL28020267 | 0.74 | CES2 (0.51) | MEN1KMT2AALDH1A1MAPTCES2 | |
| Hydrochloric Acid SCHEMBL11726341 | 0.74 | TP53 (0.49) | TSHRMAPK1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025046420-A1 | COMPOUND TARGETING EGR-1 AND USE THEREOF FOR TREATMENT OF ATOPIC DERMATITIS | 주식회사 아제라메디 | 2025-03-06 | — | — | WO | disclosed |
| EP-2550266-B1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTICS SOLUTIONS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9212151-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-8957216-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS INC (US) | 2013-05-16 | — | — | US | disclosed |
| EP-2550266-A2 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | Amitech Therapeutics Solutions, Inc. (US) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011119894-A2 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | KINAGEN, INC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | MAP4K2, MAP3K20, MAP3K19 | HTR3E 2036/4885HTR3B 1838/4885HTR3A 2534/4885 |
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | MAP4K2, MAP3K20, MAP3K19 | HTR3E 2036/4885HTR3B 1838/4885HTR3A 2534/4885 |
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | MAP4K2, MAP3K20, MAP3K19 | HTR3E 2036/4885HTR3B 1838/4885HTR3A 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.